Our results showed that BBG treatment significantly inhibited the overexpression of IL-1β, caspase-1, and NLRP3 (Figures 5(d)–5(g)), indicating that targeting P2X7R to block the ATP-induced NLRP3-caspase-1-IL-1β signaling pathway alleviates MSU crystal-induced gout inflammation in rats. The gene discussed is NLRP3; the disease is gout.